Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-031 in Duchenne Muscular Dystrophy
NCT01099761Phase 2Terminated
- Start
- Apr 2010
- Primary completion
- Jun 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ramatercept in Duchenne muscular dystrophy (DMD) (3 arms). Primary endpoints: Number of Subjects With Adverse Reactions at 24 weeks and Number of Subjects With Clinical Laboratory Adverse Reactions at 24 weeks. Started Apr 2010; status: terminated.
02
Drugs
ramatercept
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01099761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01099761.